TH Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Theratechnologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.70 |
| 52 Week High | CA$3.43 |
| 52 Week Low | CA$1.59 |
| Beta | 1.72 |
| 11 Month Change | -9.57% |
| 3 Month Change | -1.45% |
| 1 Year Change | -16.67% |
| 33 Year Change | -90.18% |
| 5 Year Change | -89.61% |
| Change since IPO | -92.44% |
Recent News & Updates
Recent updates
Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH)
May 03
Theratechnologies Inc.'s (TSE:TH) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Apr 10Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts
Feb 24Investors Don't See Light At End Of Theratechnologies Inc.'s (TSE:TH) Tunnel And Push Stock Down 27%
Feb 07The Market Doesn't Like What It Sees From Theratechnologies Inc.'s (TSE:TH) Revenues Yet
Apr 17Shareholder Returns
| TH | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -1.7% | -8.5% | 0.7% |
| 1Y | -16.7% | 1.5% | 21.7% |
Return vs Industry: TH underperformed the Canadian Biotechs industry which returned -0.4% over the past year.
Return vs Market: TH underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| TH volatility | |
|---|---|
| TH Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: TH has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: TH's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 103 | Paul Lévesque | www.theratech.com |
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.
Theratechnologies Inc. Fundamentals Summary
| TH fundamental statistics | |
|---|---|
| Market cap | CA$77.25m |
| Earnings (TTM) | -CA$4.42m |
| Revenue (TTM) | CA$117.88m |
0.7x
P/S Ratio-17.7x
P/E RatioIs TH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TH income statement (TTM) | |
|---|---|
| Revenue | US$84.32m |
| Cost of Revenue | US$19.42m |
| Gross Profit | US$64.90m |
| Other Expenses | US$68.06m |
| Earnings | -US$3.16m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.069 |
| Gross Margin | 76.97% |
| Net Profit Margin | -3.75% |
| Debt/Equity Ratio | -290.4% |
How did TH perform over the long term?
See historical performance and comparison